Ignite Creation Date:
2024-05-06 @ 3:49 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04768270
Status:
RECRUITING
Last Update Posted:
2023-08-31
First Post:
2021-02-20
Brief Title:
The Culture of Ovarian Cancer Organoids and Drug Screening
Sponsor:
Chongqing University Cancer Hospital
Organization:
Chongqing University Cancer Hospital
Study Overview
Official Title:
Drug Screening of Patient-derived Organoids From Ovarian Cancer Culture to Personalized Therapyan Exploratory Research
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The tumor organoids platform can provide the precise genetic information and phenotype as well as the heterogeneity of the tumor thus provide information on drug sensitivity specific to the patientThis is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancerOC patients
Detailed Description:
Tissue will be received from operative specimens primary ovarian carcinoma at time of primary cytoreductive surgeryOvarian cancerOC organoids will be then cultured Organoids will be validated with a combination of Next Generation Sequencing NGS analysis and immunohistochemistry TP53 PAX8 etc After then the patient-derived organoids cultured from OC will be compared the sensitivity to standard regimens chemotherapies and targeted agents recommendated by NCCN guidlines versus patients treated in clinical practice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None